Hong Kong, 30 August 2022
Opharmic Named to Forbes Asia “100 to Watch” 2022 List
Opharmic Technology (HK) Limited is proud to announce its inclusion in the prestigious Forbes Asia “100 to Watch” 2022 list. This annual recognition highlights the most promising companies and entrepreneurs across the Asia-Pacific region who are driving innovation and demonstrating strong growth potential.
Being selected for this list is a significant achievement for Opharmic, underscoring the company’s rapid progress and the transformative potential of its non-invasive ultrasound technologies.
The company’s core platforms, MeticTouch® and MeticStim®, are at the heart of this recognition. MeticTouch® enables enhanced ocular drug delivery through safe, targeted ultrasound-mediated permeability, offering a non-invasive alternative to traditional methods. MeticStim® leverages precise ultrasound cell stimulation for multiple applications.
This accolade reflects not only the scientific innovation behind Opharmic’s technologies but also the strength of its team and strategic vision.
“We are deeply honored to be recognized by Forbes Asia among the region’s most promising companies,” said Dr. Langston Suen, CEO of Opharmic Technology. “This recognition validates our commitment to developing groundbreaking, ultrasound solutions that can improve patient outcomes and accessibility. It further motivates our team as we advance toward development milestones and strategic collaborations.”
Moving forward, Opharmic will continue to advance its pipelines, with a strong focus on product development and expanding partnerships to bring its technologies to market. The company remains dedicated to its mission of transforming healthcare through accessible, ultrasound-based innovations.
Opharmic Technology